Myocilin Mt.1 Gene Promoter Single Nucleotide Polymorphism (-1000c>g) In Brazilian Patients With Primary Open Angle Glaucoma

Background: The myocilin (MYOC) gene promoter polymorphism -1000C>G (MYOC mt.1) can be associated with faster progression of primary open angle glaucoma (POAG). The purpose of this study was to investigate the MYOC mt.1 in Brazilian patients with POAG and to evaluate its possible role on the phenotype and the severity of the disease. Material and methods: One hundred sixty-seven POAG patients and 130 normal controls were enrolled. DNA samples were prepared and the MYOC mt.1 polymorphism was screened by real-time polymerase chain reaction (RT - PCR) in an Single-nucleotide polymorphism (SNP) assay. Frequencies of the MYOC mt.1 promoter polymorphism were determined for both groups and compared by Fisher's exact test and Chi-square test with Yate's correction. Intraocular pressure (IOP), cup-to-disc ratio (C/D), number of glaucoma medications, and number of glaucoma surgeries were compared between MYOC mt.1 carriers and non-carriers. Results: MYOC mt.1 genotype frequencies did not differ between POAG and controls (P = 0.420); 14.6% of controls and 16.4% of POAG patients were MYOC mt.1 carriers (CG or GG). Frequencies of the G allele were similar between glaucomatous patients and controls (7.3% and 9.2%, respectively; P = 0.477). Among POAG patients, there were no differences in mean C/D ratio, IOP, number of glaucoma medications, and surgical procedures for IOP control between carries and non-carriers of the MYOC mt.1 promoter polymorphism (p>0.05). Conclusion: The G allele of the MYOC mt.1 promoter polymorphism was equally distributed among POAG patients and healthy subjects and it is possibly unrelated to the risk and severity of disease in the Brazilian population. © 2011 Informa Healthcare USA, Inc.3211823Quigley, H.A., Broman, T.A., The number of people with glaucoma worldwide in 2010 and 2020 (2006) Br J Ophthalmol, 90, pp. 262-267Leske, M.C., Connel, A.M.S., Wu, S.Y., Risk factors for openangle glaucoma: The Barbados eye study (1995) Arch Ophthalmol, 113, pp. 918-924Wolfs, R.C.W., Klaver, C.C.W., Ramrattan, R.S., Genetic risk of primary open-angle glaucoma (1998) Arch Ophthalmol, 116, pp. 1640-1645Mitchell, P., Cumming, R.G., Mackey, D.A., Inhaled corticosteroids, family history, and risk of glaucoma (1999) Ophthalmology, 106 (12), pp. 2301-2306Stone, E.M., Fingert, J.H., Alward, W.L.M., Nguyen, T.D., Polansky, J.R., Sunden, S.L.F., Nishimura, D., Sheffield, V.C., Identification of a gene that causes primary open angle glaucoma (1997) Science, 275 (5300), pp. 668-670. , DOI 10.1126/science.275.5300.668Kubota, R., Noda, S., Wang, Y., Minoshima, S., Asakawa, S., Kudoh, J., Mashima, Y., Shimizu, N., A novel myosin-like protein (myocilin) expressed in the connecting cilium of the photoreceptor: Molecular cloning, tissue expression, and chromosomal mapping (1997) Genomics, 41 (3), pp. 360-369. , DOI 10.1006/geno.1997.4682Kirstein, L., Cvekl, A., Chauhan, B.K., Tamm, E.R., Regulation of human myocilin/TIGR gene transcription in trabecular meshwork cells and astrocytes: Role of upstream stimulatory factor (2000) Genes to Cells, 5 (8), pp. 661-676. , DOI 10.1046/j.1365-2443.2000.00355.xGould, D.B., Reedy, M., Wilson, L.A., Smith, R.S., Johnson, R.L., John, S.W.M., Mutant myocilin nonsecretion in vivo is not sufficient to cause glaucoma (2006) Molecular and Cellular Biology, 26 (22), pp. 8427-8436. , DOI 10.1128/MCB.01127-06Colomb, E., Nguyen, T.D., Bechetoille, A., Dascotte, J.-C., Valtot, F., Brezin, A.P., Berkani, M., Garchon, H.-J., Association of a single nucleotide polymorphism in the TIGR/MYOCILIN gene promoter with the severity of primary open-angle glaucoma (2001) Clinical Genetics, 60 (3), pp. 220-225. , DOI 10.1034/j.1399-0004.2001.600308.xPolansky, J.R., Juster, R.P., Spaeth, G.L., Association of the myocilin mt.1 promoter variant with the worsening of glaucomatous disease over time (2003) Clinical Genetics, 64 (1), pp. 18-27. , DOI 10.1034/j.1399-0004.2003.00099.xAlward, W.L.M., Kwon, Y.H., Khanna, C.L., Johnson, A.T., Hayreh, S.S., Zimmerman, M.B., Narkiewicz, J., Stone, E.M., Variations in the myocilin gene in patients with open-angle glaucoma (2002) Archives of Ophthalmology, 120 (9), pp. 1189-1197Fan, B.J., Leung, Y.F., Pang, C.P., Polymorphisms in the myocilin promoter unrelated to the risk and severity of primary open-angle glaucoma (2004) J Glaucoma, 13, pp. 377-384Özgül, R.K., Bozkurt, B., Orcan, S., Myocilin mt1 promoter polymorphism in Turkish patients with primary open angle glaucoma (2005) Mol Vis, 11, pp. 916-921Saura, M., Cabana, M., Ayuso, C., Valverde, D., Mutations including the promoter region of myocilin/TIGR gene (2005) European Journal of Human Genetics, 13 (3), pp. 384-387. , DOI 10.1038/sj.ejhg.5201299Melki, R., Belmouden, A., Brezin, A., Myocilin analysis by DHPLC in French POAG patients: Increased prevalence of Q368X mutation (2003) Hum Mutat, 22, pp. 179-184Vasconcellos, J.P.C., Melo, M.B., Menezes, F., Mutações no gene TIGR/MYOC em uma população brasileira com glauoma juvenil e glaucoma primário de ângulo aberto (1988) Arq Bras Oftalmol, 61, pp. 690-693Paolera, M.D., Vasconcellos, J.P.V., Umbelino, C.C., CYP1B1 Gene analysis in primary congenital glaucoma Brazilian patients (2010) J Glaucoma, 19, pp. 176-182Liu, T., Zeng, D., Zeng, C., Association between MYOC.mt1 promoter polymorphism and risk of primary open-angle glaucoma: A systematic review and meta-analysis (2008) Med Sci Monit, 14, pp. RA87-RA93Copin, B., Brezin, A.P., Valtot, F., Apolipoprotein E-promoter single-nucleotide polymorphisms affect the phenotype of primary open-angle glaucoma and demonstrate interaction with the myocilin gene (2002) Am J Hum Genet, 70, pp. 1575-1581Kerrigan-Baumrind, L.A., Quigley, H.A., Pease, M.E., Kerrigan, D.F., Mitchell, R.S., Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons (2000) Investigative Ophthalmology and Visual Science, 41 (3), pp. 741-74

A Single Nucleotide Variant In The Promoter Region Of 17β-hsd Type 5 Gene Influences External Genitalia Virilization In Females With 21-hydroxylase Deficiency

In 21-hydroxylase deficiency (21-OHD), there is an influence of genotype on the severity of external genitalia virilization. However, females carrying mutations predicting a similar impairment of enzymatic activity present a wide variability of genital phenotypes. In such cases, interindividual variability in genes related to the sex steroid hormone pathway could play a role. Objective: To evaluate the influence of POR, HSD17B5 and SRD5A2 variants on the severity of external genitalia virilization in 21-OHD females. Design and Patients: Prader stages were evaluated in 178 females with 21-OHD from a multicenter study. The 21-OHD genotypes were divided into two groups according to their severity: severe and moderate. The influences of the POR p.A503V, HSD17B5 c.-71A>G, HSD17B5 c.-210A>C, and SRD5A2 p.A49T and p.V89L variants on the degree of external genitalia virilization were analyzed. Results: The POR p.A503V, HSD17B5 c.-71A>G, HSD17B5 c.-210A>C, and SRD5A2 p.A49T and p.V89L variants were found in 25, 33, 17, 1, and 31% of the alleles, respectively. In uni- and multilinear regression, HSD17B5 c.-210A>C has a significant influence on the degree of external genitalia virilization. This variant was also identified with a higher frequency in the most severely virilized females. Conclusion: We demonstrated that a variant in the promoter region of HSD17B5 related to fetal androgen synthesis influences the genital phenotype in 21-OHD females. © 2016 S. Karger AG, Basel.85533333